A B S T R A C T To improve understanding of the mechanisms by which ADP is degraded during passage through the pulmonary vascular bed, we examined cultured endothelial and smooth muscle cells of bovine pulmonary artery for their abilities to metabolize [8-"C]ADP. ADP is rapidly converted to AMP and then to adenosine, hypoxanthine, and inosine. Inosine is the major metabolite produced by endothelial cells. Radioactivity (5-10%) is accumulated intracellularly primarily as ATP. Medium containing 50,.M ADP incubated with endothelial cells rapidly loses its ability to aggregate platelets and becomes antiaggregatory under conditions in which prostacyclin is absent. The antiaggregatory activity is probably the result of accumulated adenosine. 10 ,uM dipyridamole inhibits cellular uptake of radioactivity by >90%, and inosine in the medium is largely replaced by adenosine. This is accompanied by increased antiaggregatory activity ofconditioned medium, which can be matched by authentic adenosine at the same concentration. 1 mM aspirin had no effect on the metabolism of ADP by endothelial cells. Our results suggest: (a) Metabolism of ADP during passage through the lung is mainly the result of endothelial ADPase. (b) ADP released from aggregating platelets can be converted to the antiaggregatory substance, adenosine. Dipyridamole may exert some of its antithrombotic actions by preventing the intracellular uptake ofadenosine, thereby increasing its concentration near the site ofthrombus formation. (c) The ability ofthe vessel wall to degrade ADP should not be compromised by the use of aspirin as an antithrombotic drug. (d) Endothelium may retain some of its antithrombogenicity when prostacyclin generation is impaired.
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INTRODUCTION
Although the lung can trap and remove large numbers of thromboemboli presented to it via the systemic circulation (1), uncontrolled platelet aggregation in the lung would rapidly prove fatal. At least two protective mechanisms appear to exist to prevent this. First, the lung may continuously produce antiaggregatory prostacyclin (PGI2)' (2) (3) (4) ; second, the pulmonary vessels possess an active ADPase that rapidly degrades the important mediator of platelet aggregation, ADP (5, 6 ). An additional function of pulmonary ADPase may be to prevent the entry of ADP into the systemic circulation, thereby complementing the postulated systemic antithrombotic functions of PGI2.
To determine more precisely the location of pulmonary vascular ADPase, we have examined the metabolism of ADP by cultured cells derived from bovine pulmonary artery. Our results show that both endothelial and smooth muscle cells rapidly metabolize ADP and produce antiaggregatory adenosine. We have also studied the effects of dipyridamole and aspirin, both of which are currently undergoing clinical trials as antithrombotic drugs (i.e., the Persantineaspirin reinfarction study). Dipyridamole was of particular interest because it inhibits the intracellular uptake of adenosine in several systems, including cultured endothelial cells (7, 8) and lung (9, 10) . Our results provide additional information on the antithrombotic actions of dipyridamole and also suggest that the ability of the vessel wall to degrade ADP will not be compromised by the use of aspirin as an antithrombotic drug.
METHODS
Materials for the preparation of cell culture medium were obtained from Gibco Laboratories, Grand Island Biological Co., IAbbreviation used in this paper: PGI2, prostacyclin.
J. Clin [3H]Benzoyl-Phe-Ala-Pro-OH was used as the substrate for angiotensin-converting enzyme assay and was synthesized as described (11) .
Cell culture. Endothelial cells were obtained by treatment of bovine pulmonary arteries with 0.2% collagenase (12) . Smooth muscle cells were obtained from the same vessels (13) . Cells were growth in Eagle's minimal essential medium containing 2 mM L-glutamine and supplemented with 20% heat-inactivated (56°C for 30 min) fetal calf serum, 50 ug/ml streptomycin, 50 U/ml penicillin, 100 ,ug/ml fungizone, and 100,ug/ml kanomycin.
Criteria for the morphological and biochemical characterization of our endothelial cell cultures have been described in detail previously (12) . Endothelial cells grew as contactinhibited monolayers with a "cobblestone" morphology. Electron microscopic examination of thin sections indicated large numbers of caveolae, occasional Weibel-Palade bodies, and the full complement of organelles characteristic of endothelial cells in situ. The cells were reactive with antibodies to human Factor VIII and human a2-macroglobulin, as indicated by indirect immunofluorescence (12) . The endothelial monolayers possessed angiotensin-converting enzyme activity assayed with [3H]benzoyl-Phe-Ala-Pro-OH (11, 12) . Primary cultures, at least 98% endothelial by inspection in the inverted microscope, were purified by differential adherence techniques over the lst-3rd passages (12, 14) . Endothelial cultures used for the experiments described in this paper were from the 4th-9th passages, thus eliminating the possibility of contaminating cell types such as smooth muscle or fibroblasts. All cultures were examined by phase microscopy before use. Smooth muscle cells were larger and flatter than endothelial cells, contained dense bodies, and grew to form characteristic "ridges" (13) .
Incubations. Confluent layers of cells in 35-mm dishes (-3 x 105 cells/dish) were incubated with a 1 ml serum-free medium containing 50 ALM [8-14C]ADP, 0.5 ,uCi/ml, or 20 ,uLM [8-_4C] 1 h with serum-free medium containing 1 mM aspirin. The medium was discarded and the cells were washed several times with fresh serum-free medium before incubation with ADP. For dipyridamole studies, the drug was dissolved according to the manufacturer's instructions and added to cells simultaneously with ADP.
Thin-layer chromatography. Aliquots of conditioned medium or cell extracts were applied to silica gel plates containing a fluorescent indicator. Authentic ATP, ADP, AMP, adenosine, inosine, hypoxanthine, and adenine were applied to the plates as standards. The plates were developed in the system isobutyl alcohol/amyl alcohol/ethylene glycol monoethyl ether/ammonia/water, 45:30:90:45:60 (17) . Typical Rf values obtained with a solvent front height of 18 cm were: ATP 0.18, ADP 0.29, AMP 0.43, inosine 0.63, hypoxanthine 0.72, adenosine 0.74, adenine 0.84. Better separation of nucleosides and bases was obtained by chromatography of samples in the solvent system n-butanol/ethyl acetate/methanol/ammonia, 7:4:3:4 (18) . TypicalRfvalues obtained with this system were: inosine 0.23, hypoxanthine 0.49, adenosine 0.56, adenine 0.69, whereas ATP, ADP,, and AMP remained at or near the origin. Standards were visualized under ultraviolet light, and appropriate zones were cut out and transferred to scintillation vials. The purines were eluted with 1 ml water, Riafluor was added, and radioactivity was determined in a liquid scintillation counter. Recovery of radioactivity from the plates was routinely >90% of that applied.
Platelet aggregation. Venous blood from human volunteers was anticoagulated with one ninth vol 110 mM trisodium citrate, centrifuged at 200 g for 10 min to obtain platelet-rich plasma (PRP), and then further centrifuged at 1000 g for 20 min to obtain platelet-poor plasma. Platelet aggregation was determined turbidometrically (19) using a Bio/Data aggregometer (Bio/Data Corp., Willow Grove, Pa.). For calculation of apparent ADP concentration in conditioned medium, samples were diluted with fresh medium so that 50 ,lp of the mixture added to 450 ,lI platelet-rich plasma gave only primary (reversible) aggregation, which was compared with the aggregation obtained with authentic ADP. The lowest concentration of ADP that could be detected in medium was 2 ,uM.
RESULTS
Metabolism of ADP and adenosine by pulmonary artery endothelial and smooth muscle cells. Incubation of ADP with endothelial cells led to a time-dependent reduction in the concentration of nucleotide in the cell medium, concomitant with a decrease in the ability of the medium to aggregate platelets (Fig. 1) .
The estimated half-life of50 ,uM ADP in 1 ml incubated with -3 x 105 cells was 9 min at this substrate concentration, representing a rate of metabolism of -2.8 nmol/min per 3 x 105 cells. Analysis of cell medium showed that the disappearance of ADP was accompanied by the appearance of AMP, which reached a peak at -15 min, and adenosine, which reached a plateau at -15 min (Fig. 2A) . Hypoxanthine and inosine were also formed, and their concentrations increased throughout the incubation. Inosine was the major product after 30 min incubation. ATP and adenine were not detected in cell medium. Examina (Fig.  2B) . The major metabolite produced by smooth muscle cells was adenosine.
Effects of aspirin and dipyridamole on ADP metabolism by endothelial cells. Preincubation of cells for 60 min with 1 mM aspirin had no effect on their ability to metabolize ADP, which was measured both chromatographically and by platelet aggregation (Fig. 1) . Aspirin also had no effect on the subsequent production of metabolites. This relatively high dose of aspirin abolishes PGI2 production by endothelial cells derived from porcine aorta (20) and human umbilical vein (21) , and abolishes prostaglandin production by bovine pulmonary artery endothelial cells (unpublished observations). ADPase in rat pulmonary vessels is similarly unaffected by high doses of aspirin (5) . Therefore, these results suggest that the ability ofendothelium to degrade ADP can be maintained when PGI2 production is seriously impaired.
Dipyridamole produced an apparent stimulation of ADPase because medium from endothelial cells incubated with ADP plus 10 ,uM dipyridamole lost its platelet aggregating ability more rapidly than corresponding medium from cells incubated with ADP alone (Fig. 3) . However, chromatographic analysis indicated that dipyridamole had no effect on the degradation of ADP but, rather, significantly altered the pattern of metabolites subsequently produced (Fig. 4) . In the presence of dipyridamole, intracellular radioactivity was reduced by >90%, and inosine and hypoxanthine in the medium were reduced by 80%, being replaced by adenosine, which became the major product. When dipyridamole-treated cells were incubated with 20 ,uM [8-'4C] adenosine, intracellular radioactivity was also reduced by >90%, and inosine and hypoxanthine in the medium were reduced by 70%. The effects of dipyridamole were rapidly reversible; no effects were observed when cells were ADP Metabolism by Pulmonary Arterial Cells incubated for 60 min with 50-100 ,uM dipyridamole, washed, and then incubated with ADP. Adenosine inhibits ADP-induced platelet aggregation, but hypoxanthine and inosine do not (19) . The apparent stimulation of ADPase produced by dipyridamole, which was observed in the platelet assay, may therefore have been the result of the accumulation of adenosine at the expense of hypoxanthine and inosine. Consistent with this hypothesis is the finding that medium from cells incubated for 60 min with ADP plus dipyridamole was directly antiaggregatory under conditions in which PGI2 was absent (Fig. 5) . Chromatographic analysis indicated that the concentration of adenosine in these samples was -30 ,uM. Fig. 5 also shows that 30 ,zM authentic adenosine possessed the same inhibitory activity as conditioned medium. Moreover, medium from cells incubated for 60 min with ADP alone was weakly antiaggregatory, which is consistent with the lower concentrations of adenosine present in this medium. These results cannot be explained in terms of dipyridamole in the incubation medium being carried over into the platelet assay because untreated medium containing 10 ,uM dipyridamole had no effect on the response of platelets to ADP. The increased antiaggregatory properties of medium derived from dipyridamole-treated cells was, therefore, most likely the result of elevated levels of adenosine. However, these experiments do not rule out the possibility that endothelial cells produced an as yet unidentified, nonlabile inhibitor of aggregation when treated with dipyridamole. DISCUSSION Adenosine-5'-diphosphate is almost completely metabolized during a single passage through the pulmonary circulation, the initial step being catalyzed by an ADPase located at or near the lumen of the blood vessels (5) . The present studies show that endothelial cells derived from bovine pulmonary artery rapidly metabolize ADP, the estimated initial rate being -2.8 nmol/min per 3 x 105 cells, at a substrate concentration of 50 MM. If the endothelial cells of the capillary bed possesses similar activity, their enormous numbers (at least 1011 cells in the pulmonary capillary bed of humans), together with their direct contact with circulating blood, suggest that the pulmonary endothelium should be capable of degrading ADP at a rate of -14 ,umol/s. Although extrapolation from data obtained with cultured cells to the situation obtaining in vivo may be difficult, our results nevertheless suggest that endothelial cells can fully account for the disappearance of ADP during passage through the pulmonary circulation. Similar calculations suggest that uptake into endothelium can account for the removal of adenosine by the pulmonary vascular bed (8) . Our results show that smooth muscle cells also rapidly metabolize ADP. The significance of this is not clear, although smooth muscle ADPase may become relatively more important after damage to the vessel wall. ADPase activity is present in human venous endothelial cells and skin fibroblasts (22, 23) and in porcine aortic smooth muscle cells (6), but apparently not in human venous smooth muscle cells (22) or HeLa cells (unpublished observations).
The nature and time course of product formation suggest that the metabolism of ADP by pulmonary artery endothelial cells proceeds as follows: ADP is converted extracellularly to AMP and then to adenosine. This probably proceeds through the sequential action of ADPase and 5'-nucleotidase. However, the specificity of endothelial ADPase is not yet determined; hence, ADPase may contribute to the metabolism of AMP. Adenosine is taken up into the cell, and at these concentrations a minor portion is incorporated into nucleotides, whereas the remainder is deaminated to inosine. Inosine, in turn, may be converted to hypoxanthine by the action of nucleoside phosphorylase. Both inosine and hypoxanthine are released extracellularly. Inosine is the major product in lungs perfused with ADP or adenosine (5, 10) and may protect the pulmonary vessels against hypoxia (24) .
The cellular distribution ofthe nucleotide-degrading enzymes would seem to support this scheme. Studies using homogenates of our endothelial cells and rabbit aortic cells have shown that ADPase activity occurs in fractions enriched with 5'-nucleotidase and angiotensin-converting enzyme, both of which are localized to the plasma membrane (25) (26) (27) . Adenosine deaminase is generally considered to be intracellular, as is nucleoside phosphorylase (28) . The changes in metabolite distribution observed with dipyridamole (Fig. 4) , which at 10 uM inhibits adenosine uptake but not adenosine deaminase (29, 30) , further support this scheme of ADP metabolism.
The potent antiaggregatory and disaggregatory properties of PGI2, together with its postulated continuous release into the circulation (2-4), have led to the suggestion that PGI2 is a major mechanism whereby healthy vessels maintain their antithrombogenicity. However, under conditions where controlled platelet aggregation is necessary, i.e., to effect repair of a damaged vessel, an active ADPase may contribute to the desired fine control of hemostasis. Furthermore, the opposing actions of ADP and adenosine on platelet aggregation suggest that a balance between ADPase, 5'-nucleotidase, and the adenosine-metabolizing system may also significantly influence thrombus formation. This concept is reinforced by the recent finding that cultured porcine endothelial cells selectively release adenine nucleotides when exposed to thrombin or mechanical trauma (31) . The release leads initially to an extracellular accumulation of ADP, which is then converted via AMP to adenosine. Our results show that the nucleotidase system of endothelial cells is not inhibited by a relatively high dose of aspirin, suggesting not only that the ability of the vessel wall to degrade ADP will not be compromised by the use of aspirin as an antithrombotic drug, but also that endothelium may retain at least some of its antithrombogenicity when PGI2 production is seriously impaired.
The results obtained with dipyridamole are particularly interesting. Although this drug at concentrations of 50 MM or more directly inhibits ADP-induced platelet aggregation and thromboxane synthesis (32), blood levels in vivo are unlikely to exceed 10 MuM (33) . Clearly, the effects of dipyridamole in vivo are not explained by these actions. Moncada and Korbut (34) have recently postulated that the antithrombotic actions of dipyridamole are the result of synergism between its phosphodiesterase-inhibiting property and the adenyl cyclase-stimulating property of PGI2, resulting in elevated levels of platelet cyclic adenosine-3', 5'-monophosphate. The observation that 2 ,uM dipyridamole can inhibit platelet phosphodiesterase (32) supports their hypothesis. However, in these studies, antithrombotic activity was assessed in terms of reversal of platelet build-up on tendons superfused with ADP (35) . Aspirin has recently received attention as a potential antithrombotic drug. However, it may be difficult to select a dose that will inhibit platelet thromboxane synthesis while leaving vascular PGI2 synthesis unimpaired (36) . Given the difficulties of extrapolation from an in vitro system to conditions obtaining in vivo, our results nevertheless suggest that dipyridamole given in combination with aspirin may be desirable not only to render platelets more sensitive to PGI2 but to enhance the antithrombotic potential of the endothelial ADPase svstem shouild PGI2 synthesis be mpaire(l.
